Cancel claim 8.

Cancel claim 9.

11. (Once Amended) A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug having a dose to aqueous solubility ratio greater than 100 mL and HPMCAS, said dispersion effecting, *in vivo*, a maximal observed blood drug concentration (C_{max}) that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug.

Cancel claim 12.

Cancel claim 14.

~~15~~. (Once Amended) A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug having a dose to aqueous solubility ratio greater than 100 mL and HPMCAS, said dispersion effecting, *in vivo*, an area under a curve (AUC) plotting the serum or plasma concentration of drug along the ordinate against time on the abscissa that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug.

Cancel claim 16.

Cancel claim 18.

Cancel claim 19.

Cancel claim 20.

Cancel claim 21.

~~28~~. (Once Amended) A composition as defined in claims 1, ~~7~~, 11, ~~15, 39, 43,~~ ~~45~~, or ~~47~~ wherein said drug is a glycogen phosphorylase inhibitor.

~~29~~. (Once Amended) A composition as defined in claims 1, ~~7~~, 11, ~~15, 39, 43,~~ ~~45~~, or ~~47~~ wherein said drug is



or a pharmaceutically acceptable salt thereof.

30. (Once Amended) A composition as defined in claims 1, 8, 11, 14, 17, 20, or 45, or 47 wherein said drug is



or a pharmaceutically acceptable salt thereof.

31. (Once Amended) A composition as defined in claims 1, 8, 11, 14, 17, 20, or 45, or 47 wherein said drug is a 5-lipoxygenase inhibitor.

32. (Once Amended) A composition as defined in claims 1, 8, 11, 14, 17, 20, or 45, or 47 wherein said drug is



or a pharmaceutically acceptable salt thereof.

33. (Once Amended) A composition as defined in claims 1, 8, 11, 14, 17, 20, or 45, or 47, wherein said drug is a corticotropic releasing hormone (CRH) inhibitor.

34. (Once Amended) A composition as defined in claims 1, 8, 11, 14, 17, 20, or 45, or 47, wherein said drug is



or a pharmaceutically acceptable salt thereof.

36. (Once Amended) A composition as defined in claims 1, 7, 11, 15, 39, 43, 45, or 47, wherein said drug is



or a pharmaceutically acceptable salt thereof.

37. (Once Amended) A composition as defined in claims 1, 7, 11, 15, 39, 43, 45, or 47, wherein said drug is an antipsychotic.

38. (Once Amended) A composition as defined in claims 1, 7, 11, 15, 39, 43, 45, or 47, wherein said drug is ziprasidone.

39. (Once Amended) A composition as defined in claims 1, 7, 11, 15, 39, 43, 45, or 47, wherein said drug is selected from griseofulvin, nifedipine, and phenytoin.

The following new claims 39 to 48 have been added.

39. A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug that is crystalline when undispersed, and hydroxypropylmethylcellulose acetate succinate (HPMCAS), said dispersion providing a maximum concentration of said drug in a use environment that is higher by a factor of at least 1.5 relative to a control composition comprising an equivalent quantity of undispersed drug.

40. A composition as decribed in claim 39, wherein said drug has a dose to aqueous solubility ratio greater than 100.

41. A composition as defined in claim 39, wherein said use environment is the gastrointestinal tract.

42. A composition as defined in claim 39, wherein said use environment is MFD.